Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Belite Bio Inc ADR (BLTE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BLTE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -8.84% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.15B USD | Price to earnings Ratio - | 1Y Target Price 85 |
Price to earnings Ratio - | 1Y Target Price 85 | ||
Volume (30-day avg) 47117 | Beta -1.54 | 52 Weeks Range 31.00 - 86.53 | Updated Date 03/30/2025 |
52 Weeks Range 31.00 - 86.53 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.18 |
Earnings Date
Report Date 2025-03-17 | When - | Estimate -0.3075 | Actual -0.32 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.26% | Return on Equity (TTM) -30.6% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1988889716 | Price to Sales(TTM) - |
Enterprise Value 1988889716 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -35.61 | Shares Outstanding 32281800 | Shares Floating 14030416 |
Shares Outstanding 32281800 | Shares Floating 14030416 | ||
Percent Insiders 55.04 | Percent Institutions 1.1 |
Analyst Ratings
Rating 4.6 | Target Price 79.25 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Belite Bio Inc ADR
Company Overview
History and Background
Belite Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for inherited retinal diseases with unmet medical needs like Stargardt disease and other ABCA4-related retinal disorders. Founded in 2015, the company has advanced Tinlarebant, its lead drug candidate, through clinical development. Belite Bio Inc. (ADR) represents the American Depositary Receipt of Belite Bio.
Core Business Areas
- Drug Development: Focuses on research, development, and commercialization of therapies for inherited retinal diseases.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
The leadership team includes key executives in research, development, and business operations. The company is structured around its core function of developing and testing new drug treatments.
Top Products and Market Share
Key Offerings
- Tinlarebant: Tinlarebant is Belite Bio's primary drug candidate. It is designed to reduce the serum retinol-binding protein 4 (RBP4) to impede the vitamin A (retinol) cycle for slowing the progression of Stargardt disease (STGD1). Competitors include companies developing gene therapies and other treatments targeting the underlying causes of retinal diseases.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with companies vying to develop innovative therapies for various diseases. There's a growing demand for treatments for rare and genetic disorders.
Positioning
Belite Bio is positioned as a specialist in inherited retinal diseases, with a focus on Stargardt disease and ABCA4-related conditions. Their competitive advantage lies in their specific focus and the clinical progress of Tinlarebant.
Total Addressable Market (TAM)
The market for Stargardt disease therapies is estimated to be substantial given the global prevalence. Belite Bio aims to capture a significant portion of this market with its lead drug candidate, Tinlarebant.
Upturn SWOT Analysis
Strengths
- Specialized focus on inherited retinal diseases
- Advancement of Tinlarebant through clinical trials
- Potential first-in-class therapy for Stargardt disease
Weaknesses
- Dependence on a single lead drug candidate
- High cash burn rate associated with drug development
- Limited commercial infrastructure
Opportunities
- Potential for regulatory approval of Tinlarebant
- Expansion into other inherited retinal diseases
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Competition from other companies developing retinal disease therapies
- Regulatory hurdles and delays
Competitors and Market Share
Key Competitors
- ALNY
- SRPT
- CRSP
Competitive Landscape
Belite Bio is focused on Stargardt disease, a specific inherited retinal disease. This contrasts with larger competitors who may have broader portfolios. Their advantage lies in specialization, while their disadvantage is the concentration risk.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to clinical progress and investment in R&D.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization efforts.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Tinlarebant.
Summary
Belite Bio Inc ADR is a specialized biopharmaceutical company focused on inherited retinal diseases. Its strength lies in its focus on Stargardt disease and the potential of its lead drug candidate. However, the company is highly dependent on clinical trial success and faces competition. Investors should carefully consider the risks associated with investing in a clinical-stage biotechnology company.
Similar Companies
- ALNY
- SRPT
- CRSP
- VRTX
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-party financial data providers
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investing in biotechnology companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Belite Bio Inc ADR
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2022-04-29 | Chairman of the Board of Directors & CEO Dr. Yu-Hsin Lin M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | Website https://www.belitebio.com |
Full time employees 25 | Website https://www.belitebio.com | ||
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.